| 2598 Efficacy of a Novel Synthetic Antimicrobial Peptide against Oral Bacteria | ||
|
K.F. NOVAK1, K.W. ANDERSON1, W.J. DIAMOND1, and T.A. MIETZNER2, 1University of Kentucky, Lexington, USA, 2University of Pittsburgh, PA, USA Engineered lentivirus lytic peptides (eLLPs), a conserved set of peptides derived from lentiviral transmembrane protein sequences, are broad spectrum antimicrobial agents that kill bacteria at concentrations 50 - to 100-fold lower than those required to lyse erythrocytes. Objectives: The efficacy of eLLPs against oral bacteria has not been evaluated. The purpose of this study was to evaluate eLLP killing of selected oral bacteria representing early, bridging and late colonizers of dental plaque. Methods: Strains of Streptococcus gordonii, Fusobacterium nucleatum or Porphyromonas gingivalis were cultured in broth media to mid-log phase, washed with phosphate buffer (PB) and resuspended in PB such that upon dilution, 105 to 106 colony forming units (cfu)/ml would be treated in the bacterial killing assay. Pseudomonas aeruginosa served as a positive control. The bacteria were incubated with two-fold dilutions of peptide (100 to 0.39µM) in 96 well plates in PB for 30 minutes at 37oC. Quantification of bacterial survival post peptide exposure was accomplished using serial 10-fold dilutions of control and test wells. Colonies of surviving bacteria were counted and compared to non-peptide treated controls to determine the amount of peptide required to reduce the cfu/ml by three orders of magnitude defined as the minimum bactericidal concentration (MBC) assessed in µM peptide. Results: All three species of oral bacteria were killed by eLLP. However, the MBC of eLLP required to kill varied, ranging from 1µM to 100µM, with F. nucleatum being the most susceptible. Ranges of peptide concentration required for killing each bacterial species were as follows: P. aeruginosa–1-2µM; S. gordonii – 12.5-25µM; F. nucleatum – 1-2µM; P. gingivalis – 50-100µM. Conclusions: These results suggest that eLLP may be an effective antimicrobial agent against select oral pathogens. This work was supported by the University of Kentucky Research Support Grant and the Kentucky Science and Technology Corporation/Kentucky Science and Engineering Foundation. | ||
| Seq #279 - Antimicrobials 9:00 AM-10:30 AM, Saturday, 12 March 2005 Baltimore Convention Center 315 | ||
|
Back to the Microbiology / Immunology and Infection Control Program
| ||